Review of the 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: What is New and Why?

  • Brian G. HowardEmail author
  • Nanette K. WengerEmail author
Women + Heart Disease (E Jackson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Women and Heart Disease


In September 2014, the 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes (NSTE-ACS) was released electronically; it was published in print 3 months later, in December 2014. The management of NSTE-ACS has evolved significantly in recent years, and a number of novel agents are now available for use (e.g., prasugrel, ticagrelor). In addition, several key diagnostic and therapeutic agents that were formerly considered hallmarks in the treatment of acute coronary syndrome have fallen out of favor (e.g., glycoprotein inhibitors, CK-MB). The 2014 AHA/ACC NSTE-ACS guideline document is the first comprehensive publication for the treatment of non-ST-elevation acute coronary syndromes since 2007; this review paper serves as an overview of the 2014 NSTE-ACS guideline, with emphasis on several paramount changes since the 2007 version.


Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS) Non-ST-Elevation Myocardial Infarction (NSTEMI) Prasugrel Ticagrelor 


Compliance with Ethical Standards

Conflict of Interest

Dr. Howard and Dr. Wenger have no relevant disclosures.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.


  1. 1.
    Amsterdam EA. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation. 2014;130:e344–426.CrossRefPubMedGoogle Scholar
  2. 2.
    Go AS. Heart disease and stroke statistics—2014 update. Circulation. 2014;129(3):e28–e292.CrossRefPubMedGoogle Scholar
  3. 3.
    Yeh RW. Population trends in the incidence and outcomes of acute myocardial infarction. NEJM. 2010;362(23):2155–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Antman E. The TIMI risk score for unstable angina/non–ST elevation MI. JAMA. 2000;284(7):835–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Thygesen K. Third universal definition of myocardial infarction. JACC. 2012;60(16):1581–98.CrossRefPubMedGoogle Scholar
  6. 6.
    Anderson J. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. JACC. 2007;50(7):e1–e157.CrossRefPubMedGoogle Scholar
  7. 7.
    Newby LK. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. JACC. 2006;47(2):312–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Volz K. Creatine kinase-MB does not add additional benefit to a negative troponin in the evaluation of chest pain. Am J Emerg Med. 2012;30(1):188–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Volz K. Should creatine kinase-MB index be eliminated in patients with indeterminate troponins in the ED. Am J Emerg Med. 2012;30(8):1574–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Meine T. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005;149(6):1043–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Becker R. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32(23):2933–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEJM. 2009;361(11):1045–57.CrossRefPubMedGoogle Scholar
  13. 13.
    Montalescot G. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. NEJM. 2013;369(11):999–1010.CrossRefPubMedGoogle Scholar
  14. 14.
    Wiviott S. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEJM. 2007;357(20):2001–15.CrossRefPubMedGoogle Scholar
  15. 15.
    Stone G. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591–602.CrossRefPubMedGoogle Scholar
  16. 16.
    Giugliano R. Early versus delayed, provisional eptifibatide in acute coronary syndromes. NEJM. 2009;360(21):2176–90.CrossRefPubMedGoogle Scholar
  17. 17.
    Smith S. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease – 2011 update. JACC. 2011;58(23):2432–46.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Stanford UniversityStanfordUSA
  2. 2.Emory University School of Medicine, Emory Heart and Vascular CenterAtlantaUSA

Personalised recommendations